Recombinant Mouse Very long-chain acyl-CoA synthetase (Slc27a2)

What is Slc27a2 and what are its primary functions?

Slc27a2 (Solute Carrier Family 27 Member 2) is a protein that functions as a very long-chain acyl-CoA synthetase, also known as Fatty Acid Transport Protein 2 (FATP2). It plays crucial roles in fatty acid metabolism, particularly in the activation and transport of long-chain and very long-chain fatty acids. The protein catalyzes the formation of fatty acyl-CoA esters from fatty acids, ATP, and CoA through the enzymatic activity EC:6.2.1.3 (Long-chain-fatty-acid--CoA ligase) . This activation is an essential step for fatty acids to participate in various metabolic pathways including β-oxidation, lipid synthesis, and cell signaling processes.

What gene synonyms and alternative protein names should researchers be aware of when researching Slc27a2?

When conducting literature searches or database inquiries, researchers should be aware of the following alternative nomenclature:

Gene synonyms:

• Acsvl1

• Facvl1

• Fatp2

• Vlacs

• Vlcs

Protein name synonyms:

• Very long-chain acyl-CoA synthetase

• Fatty acid transport protein 2

• FATP-2

• Fatty-acid-coenzyme A ligase, very long-chain 1

• Long-chain-fatty-acid--CoA ligase

• THCA-CoA ligase

• Very long-chain-fatty-acid-CoA ligase

Understanding these synonyms is critical for comprehensive literature reviews and to avoid overlooking relevant research findings.

How does Slc27a2 expression vary across different tissues in mice?

Slc27a2 is predominantly expressed in metabolically active tissues. While the provided search results don't detail the complete tissue expression profile, research has established that this protein is highly expressed in the liver and kidney, with significant expression also found in the intestine and pancreatic cells. The differential expression across tissues correlates with its functional roles in lipid metabolism and may help explain tissue-specific phenotypes observed in knockout models . Researchers should consider these expression patterns when designing tissue-specific studies or interpreting experimental results.

How does Slc27a2 deletion affect diabetic kidney disease progression in mouse models?

Genetic deletion of Slc27a2 in diabetic-prone mouse models demonstrates remarkable protective effects against diabetic kidney disease (DKD) progression. Studies using Lepr^db/db eNOS^-/- mice (a genetic model of DKD) crossed with Slc27a2^-/- mice revealed:

• Normalization of glomerular filtration rate

• Reduced albuminuria

• Improved kidney histopathology

• Extended life span compared to diabetic mice with functional Slc27a2

The mechanism appears to involve protection against lipotoxicity from albumin-bound fatty acids that are filtered across damaged glomeruli and reabsorbed by proximal tubules through FATP2-dependent mechanisms. These findings suggest that FATP2 inhibition could represent a therapeutic approach for preventing or treating DKD .

What is the relationship between Slc27a2 expression and glycemic control in diabetes models?

Slc27a2 deletion has profound effects on glycemic control in diabetic mouse models. Research demonstrates:

• DKD-prone Slc27a2^-/- mice exhibit markedly reduced fasting plasma glucose levels, approaching euglycemia despite increased obesity and decreased physical activity

• A linear relationship exists between plasma glucose levels and Slc27a2 null allele number in Lepr^db/db eNOS^-/- mice (R^2 = 0.996)

• The glucose-lowering effect is not mediated through enhanced urinary glucose excretion (glycosuria)

The mechanism involves β-cell preservation, as Slc27a2^-/- mice maintain normal insulin levels despite diabetogenic conditions. Histological examination reveals larger pancreatic islets with more β-cells in Slc27a2^-/- Lepr^db/db eNOS^-/- mice compared to their Slc27a2^+/+ counterparts .

What role does Slc27a2 play in cancer progression, specifically in renal cell carcinoma?

Recent research has identified Slc27a2 as a potential tumor suppressor in clear cell renal cell carcinoma (ccRCC). Key findings include:

These findings suggest SLC27A2 could serve as both a prognostic biomarker and a potential therapeutic target in ccRCC. The ROC curve analysis supports its potential utility as a diagnostic biomarker for ccRCC (p = 0.0067 and p < 0.0001 in different datasets) .

What are the optimal methods for generating Slc27a2 knockout mouse models?

Based on published research methodologies, the established approach for generating Slc27a2 knockout mice involves:

• Obtaining 129S-Slc27a2^tm1Kds/J mice from repositories such as Jackson Laboratory

• Backcrossing for at least 10 generations with the desired genetic background (e.g., C57BLKS/J) to create a congenic strain

• Intercrossing heterozygous mice to generate experimental knockout groups

• Confirming genotypes via PCR analysis

For studies examining Slc27a2's role in specific disease models, researchers should consider breeding these knockout mice with established disease models (e.g., Lepr^db/db eNOS^-/- for DKD studies) and carefully characterizing the resulting phenotypes across multiple parameters .

What experimental designs are most effective for studying Slc27a2 function in metabolic disorders?

Effective experimental designs for studying Slc27a2 function in metabolic disorders include:

• Genetic approaches:

  • Global Slc27a2 knockout models

  • Tissue-specific conditional knockout models

  • Gene dose studies comparing heterozygous and homozygous knockouts

• Inducible disease models:

  • High-fat diet (HFD) feeding (e.g., Teklad TD.06414, 60.3% fat, 21.3% carbohydrate, 18.4% protein)

  • Low-dose streptozotocin (STZ) treatment (e.g., 65 μg/g daily for 3 days)

  • Combination of HFD and STZ to induce type 2 diabetes and DKD

• Key measurements:

  • Blood glucose monitoring (fasting conditions)

  • Insulin secretion assays

  • Food consumption and physical activity tracking

  • Histopathological analysis of relevant tissues

  • Molecular markers of disease progression

Multiple experimental groups should be included to isolate the specific effects of Slc27a2 deletion from other variables in the model systems.

What cell culture systems are appropriate for studying Slc27a2 function in vitro?

For in vitro studies of Slc27a2 function, researchers have successfully employed:

• Cell lines:

  • Renal cancer cell lines (786-O and Caki) have been validated for Slc27a2 functional studies

  • Pancreatic β-cell lines for studies on insulin secretion

  • Hepatocyte and kidney cell lines for metabolic studies

• Genetic manipulation approaches:

  • Lentiviral vectors for Slc27a2 overexpression

  • siRNA for Slc27a2 knockdown

• Functional assays:

  • Cell proliferation assays (e.g., CCK8)

  • Migration and invasion assays

  • Metabolic flux analysis for fatty acid metabolism

  • Insulin secretion assays in pancreatic cell models

When designing in vitro experiments, researchers should verify endogenous Slc27a2 expression levels in their chosen cell line to ensure relevance to the research question.

How should researchers interpret contradictory findings regarding Slc27a2 function in different tissues?

When encountering contradictory findings regarding Slc27a2 function, researchers should consider:

• Tissue-specific effects: Slc27a2 may have different or even opposing functions in different tissues. For example, while its deletion appears protective in kidney tissue in DKD models, it may have different effects in liver or adipose tissue.

• Context-dependency: The function of Slc27a2 may differ significantly depending on pathological context. For instance, its role in normal physiology may differ from its role in diabetic conditions or cancer.

• Methodological differences: Contradictions may arise from differences in:

  • Animal models (strain, age, sex)

  • Experimental conditions (diet, housing, duration)

  • Measurement techniques and timepoints

• Compensatory mechanisms: In knockout models, other fatty acid transporters may compensate for Slc27a2 absence, potentially obscuring or altering the observed phenotype .

To resolve contradictions, researchers should design experiments that directly compare conditions within a single study and consider using conditional or inducible knockout models to minimize compensatory adaptations.

What statistical approaches are most appropriate for analyzing Slc27a2 expression data in cancer studies?

Based on published methodologies, the following statistical approaches are recommended:

• For comparing expression levels between groups:

  • Two-group comparisons: Unpaired two-tailed t-test

  • Multiple group comparisons: One-way ANOVA with Tukey's test for multiple testing of nonparametric data

• For survival analysis:

  • Kaplan-Meier curves with log-rank tests to compare survival outcomes

  • Cox proportional hazards regression for univariate and multivariate analyses to identify independent predictors

• For diagnostic value assessment:

  • Receiver Operating Characteristic (ROC) curve analysis to evaluate sensitivity and specificity

  • Area Under the Curve (AUC) calculation to quantify diagnostic performance

• For gene dose effects:

  • Linear regression analysis to determine relationships between phenotypes and Slc27a2 null allele number

Statistical significance is typically defined as p < 0.05, and researchers should report both the test statistic and exact p-values rather than simply stating significance.

What are the most promising therapeutic applications targeting Slc27a2?

Based on current research findings, the most promising therapeutic applications targeting Slc27a2 include:

• Diabetic kidney disease treatment:

  • FATP2 inhibitors may protect against lipotoxicity in proximal tubule cells

  • This approach could potentially slow DKD progression to end-stage renal disease

• Glycemic control in diabetes:

  • FATP2 inhibition might preserve β-cell function and insulin secretion

  • This could represent a novel approach for maintaining glycemic control in type 2 diabetes

• Renal cancer therapy:

  • Strategies to upregulate SLC27A2 expression might suppress tumor proliferation and invasion

  • This approach could potentially improve outcomes in ccRCC patients

Future research should focus on developing selective Slc27a2 inhibitors or activators and testing their efficacy in preclinical models before advancing to clinical studies.

What critical knowledge gaps remain in understanding Slc27a2 biology?

Despite significant advances, several important knowledge gaps remain:

• Molecular regulation:

  • The precise transcriptional and post-translational regulation of Slc27a2 remains incompletely understood

  • Factors influencing tissue-specific expression patterns require further investigation

• Substrate specificity:

  • While Slc27a2 is known to transport long-chain fatty acids, the complete profile of preferred substrates and their relative affinities is not fully characterized

  • The potential for Slc27a2 to transport other lipid species or drugs remains to be explored

• Signaling pathways:

  • The downstream signaling pathways affected by Slc27a2 activity in different tissues and disease states require further elucidation

  • How Slc27a2 interacts with other metabolic regulators remains poorly understood

• Human relevance:

  • Most studies have been conducted in mouse models, and the translation of findings to human physiology and pathology requires validation

  • Population studies examining SLC27A2 variants and their correlation with disease risk are needed

Addressing these knowledge gaps will require interdisciplinary approaches combining advanced genetic models, metabolomics, proteomics, and translational research.